Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

Abstract EN

Sorafenib is an oral angiogenetic multikinase inhibitor approved in the treatment of renal and hepatocellular carcinoma.

Bleeding and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported.

We report two cases of patients with hepatocellular carcinoma who developed a cerebrovascular accident while on sorafenib.

Neither patient had any risk factors for the cerebrovascular events apart from gender and age in the second patient.

Laboratory data were noncontributory.

The head CT scan did not reveal acute abnormalities.

No hemodynamically significant stenosis was visible in the carotid ultrasound, and the echocardiogram showed normal size of the heart chambers and normal systolic function of the left ventricle.

Sorafenib was discontinued in both cases.

Physicians should monitor patients receiving sorafenib for neurologic symptoms, and in the absence of other etiology, prompt discontinuation of this drug should be considered.